| Trial ID: | L1389 |
| Source ID: | NCT05225077
|
| Associated Drug: |
Dapagliflozin 10 Mg [Farxiga]
|
| Title: |
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Renal Insufficiency, Chronic|Cardiac Catheterization|Percutaneous Coronary Intervention
|
| Interventions: |
DRUG: Dapagliflozin 10 MG [Farxiga]
|
| Outcome Measures: |
Primary: Incidence of contrast induced nephropathy, Serum creatinine (Scr) elevation of \>25% or \>0.5 mg/dl (44 μmol/l) from baseline within 48 hours, 48 hours |
|
| Sponsor/Collaborators: |
Sponsor: Dong-A University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
600
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2022-01-01
|
| Completion Date: |
2023-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2022-02-04
|
| Locations: |
Dong A University Hospital, Busan, 602-715, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT05225077
|
